Brett Blackman is the Senior Vice President, Chief Business Officer of Valo. Over the last 20 years, Brett has leveraged his expertise as an entrepreneur, inventor, drug discovery scientist, biomedical and mechanical engineer to create transformational approaches to drug discovery.

Early in his career, Brett pioneered a cardiovascular surrogate platform technology while training at the University of Pennsylvania (Ph.D.), Harvard Medical School (postdoc), and then later as a faculty member at the University of Virginia. This work culminated in the creation of more than ten human disease models for some of the most challenging diseases and became the core technology of his first company, HemoShear Therapeutics, which was founded in 2008.

Prior to Valo and since 2016, Brett has served as the Co-Founder, Chief Scientific Officer, and strategic research advisor for several Flagship Pioneering biotechnology companies including Cogen Therapeutics (now Repertoire Immune Medicines), Omega Therapeutics, Kintai Therapeutics (now Senda Therapeutics), Ohana Biosciences, and Evelo Biosciences. Brett has a B.S. in Mechanical Engineering and Mechanics from Drexel University, a Ph.D. in Bioengineering from the University of Pennsylvania, and did his Postdoctoral Fellowship in Vascular Biology at Harvard Medical School & Brigham and Women’s Hospital.